BCR inhibitors improving CLL patient outcomes
Genetically modified T-cell therapy in multicenter trials
Genetic elements driving IMiD resistance in multiple myeloma
What’s new in minimal residual disease (MRD) detection in myeloma?
The role of transplant in the era of new treatments for lymphoma and CLL